I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
14 avr. 2021 08h30 HE
|
I-Mab
SHANGHAI, China., and GAITHERSBURG, MD, April 14, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development...
I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
06 avr. 2021 08h00 HE
|
I-Mab
SHANGHAI, China and GAITHERSBURG, Md. and SEONGNAM, South Korea, April 06, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the...
I-Mab Announces Upcoming Participation at April Conferences
31 mars 2021 08h00 HE
|
I-Mab
SHANGHAI, China and GAITHERSBURG, Md., March 31, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
30 mars 2021 08h00 HE
|
I-Mab
SHANGHAI, China and GAITHERSBURG, Md., March 30, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the development of novel...
I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
29 mars 2021 07h00 HE
|
I-Mab
18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets...
I-Mab to Host 2021 R&D Day
24 mars 2021 08h00 HE
|
I-Mab
Mandarin session on April 7, 2021 and English session on April 26, 2021 for investors and research analysts SHANGHAI, China and GAITHERSBURG, Md., March 24, 2021 (GLOBE NEWSWIRE) -- I-Mab (the...
I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
19 mars 2021 16h20 HE
|
I-Mab
SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 (GLOBE NEWSWIRE) -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
11 mars 2021 08h00 HE
|
I-Mab
SHANGHAI, China and GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...
I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
10 mars 2021 08h00 HE
|
I-Mab
- New Initiative is part of I-Mab’s long-term strategy to drive innovation and scientific leadership in immuno-oncology- New collaborations signed will allow I-Mab access to cutting edge technology...
I-Mab Filed 2019 Annual Report on Form 20-F
29 avr. 2020 09h24 HE
|
I-Mab
SHANGHAI, China and ROCKVILLE, MD., April 29, 2020 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and...